TY - JOUR
T1 - Loop diuretics are open-channel blockers of the cystic fibrosis transmembrane conductance regulator with distinct kinetics
AU - Ju, Min
AU - Scott-ward, Toby S
AU - Liu, Jia
AU - Khuituan, Pissared
AU - Li, Hongyu
AU - Cai, Zhiwei
AU - Husbands, Stephen M
AU - Sheppard, David N
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Background and Purpose Loop diuretics are widely used to inhibit the Na+, K+, 2Cl- co-transporter, but they also inhibit the cystic fibrosis transmembrane conductance regulator (CFTR) Cl - channel. Here, we investigated the mechanism of CFTR inhibition by loop diuretics and explored the effects of chemical structure on channel blockade. Experimental Approach Using the patch-clamp technique, we tested the effects of bumetanide, furosemide, piretanide and xipamide on recombinant wild-type human CFTR. Key Results When added to the intracellular solution, loop diuretics inhibited CFTR Cl- currents with potency approaching that of glibenclamide, a widely used CFTR blocker with some structural similarity to loop diuretics. To begin to study the kinetics of channel blockade, we examined the time dependence of macroscopic current inhibition following a hyperpolarizing voltage step. Like glibenclamide, piretanide blockade of CFTR was time and voltage dependent. By contrast, furosemide blockade was voltage dependent, but time independent. Consistent with these data, furosemide blocked individual CFTR Cl- channels with 'very fast' speed and drug-induced blocking events overlapped brief channel closures, whereas piretanide inhibited individual channels with 'intermediate' speed and drug-induced blocking events were distinct from channel closures. Conclusions and Implications Structure-activity analysis of the loop diuretics suggests that the phenoxy group present in bumetanide and piretanide, but absent in furosemide and xipamide, might account for the different kinetics of channel block by locking loop diuretics within the intracellular vestibule of the CFTR pore. We conclude that loop diuretics are open-channel blockers of CFTR with distinct kinetics, affected by molecular dimensions and lipophilicity.
AB - Background and Purpose Loop diuretics are widely used to inhibit the Na+, K+, 2Cl- co-transporter, but they also inhibit the cystic fibrosis transmembrane conductance regulator (CFTR) Cl - channel. Here, we investigated the mechanism of CFTR inhibition by loop diuretics and explored the effects of chemical structure on channel blockade. Experimental Approach Using the patch-clamp technique, we tested the effects of bumetanide, furosemide, piretanide and xipamide on recombinant wild-type human CFTR. Key Results When added to the intracellular solution, loop diuretics inhibited CFTR Cl- currents with potency approaching that of glibenclamide, a widely used CFTR blocker with some structural similarity to loop diuretics. To begin to study the kinetics of channel blockade, we examined the time dependence of macroscopic current inhibition following a hyperpolarizing voltage step. Like glibenclamide, piretanide blockade of CFTR was time and voltage dependent. By contrast, furosemide blockade was voltage dependent, but time independent. Consistent with these data, furosemide blocked individual CFTR Cl- channels with 'very fast' speed and drug-induced blocking events overlapped brief channel closures, whereas piretanide inhibited individual channels with 'intermediate' speed and drug-induced blocking events were distinct from channel closures. Conclusions and Implications Structure-activity analysis of the loop diuretics suggests that the phenoxy group present in bumetanide and piretanide, but absent in furosemide and xipamide, might account for the different kinetics of channel block by locking loop diuretics within the intracellular vestibule of the CFTR pore. We conclude that loop diuretics are open-channel blockers of CFTR with distinct kinetics, affected by molecular dimensions and lipophilicity.
UR - http://www.scopus.com/inward/record.url?scp=84890288894&partnerID=8YFLogxK
UR - http://dx.doi.org/10.1111/bph.12458
U2 - 10.1111/bph.12458
DO - 10.1111/bph.12458
M3 - Article
SN - 0007-1188
VL - 171
SP - 265
EP - 278
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 1
ER -